RxDoctor Payments Data

Kasey Lieu

Family · Snellville, GANPI 1245716505

Payments from drug & device makers

$5,169in general payments, 2019–2025

Across 272 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$914
  • Amgen$455
  • AstraZeneca$432
  • Astellas Pharma US Inc$370
  • GSK$273
  • Pfizer$265
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$5,10399%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,169 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$3,485
Medicare patients
15
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$45,928
OzempicSemaglutide27$33,458
FarxigaDapagliflozin Propanediol19$23,075
EliquisApixaban17$16,650
XareltoRivaroxaban11$13,610
MyrbetriqMirabegron12$11,492
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,537
Losartan Potassium189$1,723
Amlodipine Besylate205$1,290
Lisinopril151$1,092
Rosuvastatin Calcium117$987
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf14$981
Levothyroxine Sodium115$917
Metoprolol Succinate111$901
Gabapentin59$788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix$273$49,46552 claims
Novo NordiskOzempic$81$33,45827 claims
AstraZenecaFarxiga$432$23,07519 claims
PfizerEliquis$265$16,65017 claims
Johnson & JohnsonXarelto$120$13,61011 claims
Astellas Pharma US IncMyrbetriq$370$11,49212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$917115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →